February 22, 2021
Tissue engineering company Humacyte is about to make a special purpose acquisition company (SPAC) deal in order to go public. The company is developing bioengineered Human Acellular Vessels (HAVs), which provide prosthetic vasculature to support the repair, reconstruction, and replacement of blood vessels damaged by injury or disease. What is a SPAC? A special purpose...
